NASDAQ · INO
Healthcare · Biotechnology
$1.45
Down-$0.06 (-3.97%)
Updated Nov 11, 2026, 2:48 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · INO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
INO closed at $1.45 after 21 trading sessions, up 45.26% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $1.48 | $1.51 | $1.405 | $1.45 | 14.54M |
| Nov 9, 2026 | $1.30 | $1.60 | $1.26 | $1.51 | 31.27M |
| Nov 6, 2026 | $1.125 | $1.27 | $1.07 | $1.215 | 39.72M |
| Nov 5, 2026 | $1.57 | $1.59 | $1.40 | $1.45 | 16.58M |
| Nov 4, 2026 | $1.67 | $1.8499 | $1.55 | $1.62 | 21.38M |
| Nov 3, 2026 | $1.87 | $2.04 | $1.60 | $1.66 | 43.26M |
| Nov 2, 2026 | $1.99 | $2.17 | $1.655 | $1.89 | 222.26M |
| Oct 30, 2026 | $0.8637 | $0.8637 | $0.5961 | $0.6024 | 80.5M |
| Oct 29, 2026 | $0.9401 | $0.9698 | $0.6101 | $0.7718 | 9.64M |
| Oct 28, 2026 | $0.9298 | $0.979 | $0.9108 | $0.9286 | 4.57M |
| Oct 27, 2026 | $0.885 | $0.95 | $0.8582 | $0.89 | 3.8M |
| Oct 26, 2026 | $0.9235 | $0.94 | $0.8522 | $0.8698 | 2.97M |
| Oct 23, 2026 | $0.8505 | $0.94 | $0.8037 | $0.8971 | 3.93M |
| Oct 22, 2026 | $0.7999 | $0.9199 | $0.7812 | $0.8389 | 5.52M |
| Oct 21, 2026 | $1.06 | $1.09 | $0.7953 | $0.7953 | 11.65M |
| Oct 20, 2026 | $1.01 | $1.06 | $0.99 | $1.01 | 10.81M |
| Oct 19, 2026 | $1.01 | $1.02 | $0.98 | $1.00 | 2.12M |
| Oct 16, 2026 | $1.06 | $1.06 | $0.9864 | $0.9901 | 2.06M |
| Oct 15, 2026 | $0.9606 | $1.06 | $0.9606 | $1.04 | 1.76M |
| Oct 14, 2026 | $1.00 | $1.02 | $0.9583 | $0.986 | 3M |
| Oct 13, 2026 | $1.11 | $1.11 | $0.95 | $0.9982 | 8.56M |
The latest Smart Investors Daily articles mentioning INO.
Company
Market Activity
Research & News
INO research
Company profile and research snapshot.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Jefferies | Buy | — |
| Nov 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Jefferies | Buy | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jun 1, 2026 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Nov 4, 2026
Inovio Pharmaceuticals receives FDA Accelerated Approval for VOCERYQ in recurrent respiratory papillomatosis, prompting a rating upgrade. Click to read more.
Yahoo · Nov 2, 2026
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.
Yahoo · Nov 2, 2026
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
Yahoo · Nov 2, 2026
Inovio Pharmaceuticals (INO) shares surged Monday after the company's Friday announcement that the U
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INO.
